Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial
Authors:
Open Access
- 28 September 2023
- journal article
- research article
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 41, 100907
Abstract
No abstract availableKeywords
Funding Information
- Innovent Biologics
This publication has 30 references indexed in Scilit:
- Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 studyEuropean Heart Journal, 2016
- Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins – ODYSSEY JAPAN Randomized Controlled Trial –Circulation Journal, 2016
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular EventsNew England Journal of Medicine, 2015
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)JACC, 2014
- Effects of Evolocumab (AMG 145), a Monoclonal Antibody to PCSK9, in Hypercholesterolemic, Statin-Treated Japanese Patients at High Cardiovascular RiskCirculation Journal, 2014
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial InfarctionJAMA, 2009
- Lipoprotein(a) Levels and Risk of Future Coronary Heart DiseaseLarge-Scale Prospective DataArchives of internal medicine (1960), 2008
- Relationship of Baseline Serum Cholesterol Levels in 3 Large Cohorts of Younger Men to Long-term Coronary, Cardiovascular, and All-Cause Mortality and to LongevityJAMA, 2000